SCHEMBL2610089

SCHEMBL2610089

CC(=O)C(N)CCC(=O)ON

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.38
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
GRIA4 P48058 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIK2 Q13002 1/20 0.37
GRIK3 Q13003 1/20 0.37
GRIN2B Q13224 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27432122 0.83 SLC1A1 (0.55) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL23734825 0.83 SLC1A1 (0.55) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL17724321 0.80 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL3510151 0.80 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL1373976 0.80 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL648219 0.80 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL8697 0.80 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL10046708 0.78 SLC1A1 (0.35) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL16450883 0.78 SLC1A1 (0.35) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL16020608 0.78 SLC1A1 (0.35) SLC1A1GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101163-A1 COMPOSITION FOR INHIBITING CANCER METASTASIS TAIPEI MEDICAL UNIVERSITY (TW) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101163-A1 COMPOSITION FOR INHIBITING CANCER METASTASIS HDGF, MIF, HGF SLC1A1 75/4885GRM8 3020/4885GRM6 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.